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Abstract This study compared the relative levels of ryanodine
receptor (RyR) isoforms, inositol 1,4,5-trisphosphate receptor
(IP3R) isoforms, and calcineurin, plus their association with
FKBP12 in brain, skeletal and cardiac tissue. FKBP12 demon-
strated a very tight, high affinity association with skeletal muscle
microsomes, which was displaced by FK506. In contrast,
FKBP12 was not tightly associated with brain or cardiac
microsomes and did not require FK506 for removal from these
organelles. Furthermore, of the proteins solubilised from skeletal
muscle, cardiac muscle and brain microsomes, only skeletal
muscle RyR1 bound to an FKBP12^glutathione-S-transferase
fusion protein, in a high affinity FK506 displaceable manner.
These results suggest that RyR1 has distinctive FKBP12 binding
properties when compared to RyR2, RyR3, all IP3R isoforms
and calcineurin. ß 2001 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The 12-kDa FK506 binding protein (FKBP12), a cis^trans
prolyl isomerase, was identi¢ed originally as the cytoplasmic
receptor for the immunosuppressant drugs FK506 and rapa-
mycin [1,2]. This ubiquitously expressed protein was discov-
ered subsequently to be a crucial regulator of Ca2 release
from both ryanodine receptors (RyRs) and more recently ino-
sitol 1,4,5-trisphosphate receptors (IP3Rs) [3,4]. These recep-
tors are large tetrameric structures, both represented by three
isoforms [4] and FKBP12 or its close homologue FKBP12.6
are often described as integral subcomponents of these Ca2
release channels. This description arises mainly from studies
showing that FKBP12 binds very tightly to RyR1 from skel-
etal muscle, with su⁄cient a⁄nity to co-purify with the recep-
tor [5,6]. This tight association can be disrupted by treatment
with high concentrations of FK506 and rapamycin [7]. The
FKBP12^RyR1 interaction is required for normal and
coupled gating [8,9] of RyR1 channels, where FKBP12 re-
moval from RyR1 de-stabilises the channel, resulting in
long-lasting sub-conductance states [8]. Cardiac RyR2 can
also be found in association with FKBP12 [10] and is regu-
lated by this immunophilin [11]. However, RyR2 co-puri¢es
with the FKBP12 homologue FKBP12.6 [12,13], which has
been demonstrated to bind tightly to RyR2 in canine sarco-
plasmic reticulum (SR) and to regulate Ca2 release from
cardiac RyR2 in some [14,15] but not all [13,16] studies.
The ¢nal RyR isoform, RyR3, interacts with FKBP12
[17,18], although FKBP12 has not been shown to co-purify
or modulate Ca2 release from RyR3 [17].
Subsequent to the studies showing that FKBP12 was an
integral subcomponent of skeletal muscle RyR1, it was re-
vealed that cerebellar IP3R (predominantly the type 1 iso-
form) was also modulated by FKBP12 in a similar fashion
to RyR1, with IP3R1 and FKBP12 co-purifying through sev-
eral chromatographic steps including size-exclusion [19]. Fur-
ther studies showed that the phosphatase calcineurin bound
tightly to the IP3R complex in an FK506/rapamycin displace-
able fashion, suggesting that FKBP12 anchored calcineurin to
IP3R1 [20]. However, other functional studies have failed to
demonstrate a physiological regulation of IP3R-induced Ca2
release by FKBP12 [21]. Furthermore, very recent work has
demonstrated that mature IP3R1 does not display a speci¢c,
high a⁄nity interaction with FKBP12 [18].
It is thus far from clear whether the tight association of
FKBP12 with intracellular Ca2 release channels is a global
phenomenon found outside that demonstrated in skeletal and
cardiac muscle between RyR1^FKBP12 and RyR2^
FKBP12.6, respectively. Furthermore, with the exception of
cerebellar IP3R, nothing is known concerning the interaction
or association of FKBP12 with intracellular Ca2 release
channels in the central nervous system. This is important as
the brain has a very rich expression of RyR and IP3R iso-
forms [22^25], and contains exceptionally high levels of
FKBPs [26]. It is also unknown how widespread the described
association between FKBP12 and IP3R isoforms, as well as
FKBP12 and calcineurin is in di¡erent tissue types, or other
brain regions besides the cerebellum. Finally, previous studies
have for the most part been performed on solubilised or pu-
ri¢ed preparations, or in systems overexpressing intracellular
Ca2 release channels. It has thus been di⁄cult to gain an
understanding of the real dynamics of FKBP12^membrane
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and FKBP12^Ca2 release channel association in native tissue
preparations.
The present study therefore initially investigated the relative
distribution of RyR and IP3R isoforms with FKBP12 and
calcineurin, in crude microsomes and native membranes pre-
pared from rabbit skeletal muscle, cardiac muscle and brain.
We then determined the nature of the association between
FKBP12 and microsomes prepared from these tissues. Finally,
we investigated the FKBP12 binding ability of protein solu-
bilised from brain, cardiac and skeletal muscle microsomes,
using FKBP12^glutathione-S-transferase (GST) fusion a⁄nity
precipitation. Results found di¡ering tissue distributions of
the key Ca2 release control proteins in these tissue types,
with only skeletal muscle preparations and skeletal muscle
RyR1 found to be tightly associated with FKBP12, in an
FK506 displaceable manner. These results indicate that
RyR1 has distinctive FKBP12 binding properties when com-
pared to RyR2, RyR3, calcineurin and all IP3R isoforms.
2. Materials and methods
2.1. Preparation of crude microsomal and membrane fractions
Crude microsomal fractions from various adult rabbit tissues were
prepared by di¡erential centrifugation using a slight modi¢cation of a
method described previously [27]. Fresh skeletal muscle, cardiac
muscle and brain were dissected free of excess fat and blood vessels
and were then cut into approximately 1 cm3 pieces. Tissues were
homogenised with three 30 s bursts in an Ultra-Turrax homogeniser
(T-25 probe, maximum speed) in four volumes (per wet weight) of ice
cold homogenisation bu¡er consisting of 0.3 M sucrose, 20 mM
imidazole^HCl, pH 7.4, 0.8 mM benzamidine, 1 mM iodoacetamide,
1 Wg/ml of aprotinin, pepstatin A and leupeptin, and 0.5 mM phenyl-
methyl-sulfonyl£uoride (PMSF). Homogenates were centrifuged at
5000Ugmax for 10 min at 4‡C in a Beckman Avanti J-25 (JLA-
16.250 rotor). Particulate fractions were resuspended in four volumes
of homogenisation bu¡er and further centrifuged at 5000Ugmax for
10 min at 4‡C. The two resulting supernatants were combined and
centrifuged in a Beckman Ultracentrifuge at 100 000Ugmax for 60 min
at 4‡C (Beckman Type 42.1 rotor), to obtain the crude microsomal
membranes. Membranes were resuspended in two volumes of homog-
enisation bu¡er by gentle homogenisation using a loose ¢tting glass-
Te£on homogeniser. Both the crude microsomal membranes and
100 000Ugmax derived supernatant fractions were aliquoted and stored
at 370‡C. Total membrane and cytosolic fraction were also prepared
from the original homogenates by centrifugation at 100 000Ugmax
(Beckman Type 42.1 rotor). The derived membrane and supernatant
fractions were aliquoted and stored at 370‡C. The protein concen-
tration of the membrane and microsomal fractions was determined
using a modi¢ed version of the Lowry procedure with bovine serum
albumin as standard [28].
2.2. Sodium dodecyl sulfate^polyacrylamide gel electrophoresis
(SDS^PAGE) and immunoblotting
Proteins (20^30 Wg of protein depending on antisera used) from
membranes, crude microsomes (and when appropriate their respective
cytosolic fractions), and FKBP12^GST a⁄nity precipitations were
resolved on 15% SDS^PAGE for FKBP12 and calcineurin detection,
8% SDS^PAGE for IP3R detection and 6 or 5% SDS^PAGE for RyR
detection. Proteins were transferred electrophoretically to nitrocellu-
lose membranes (Schleicher and Schuell, 0.45 WM) using a semi-dry
blotting apparatus (32 V, 1 h) for calcineurin and FKBP12 immuno-
blotting, and a wet transfer blotting apparatus (80 V, 1 h for IP3R
detection, and 72 V, 2 h for RyR detection). The transfer bu¡er for
FKBP12, calcineurin and IP3R immunoblots consisted of 48 mM
Tris, 39 mM glycine and 20% ethanol whereas for RyR immunoblots
the transfer bu¡er was supplemented with 0.137% SDS and ethanol
was omitted. Nitrocellulose membranes were blocked for 1 h in
150 mM NaCl, 10 mM Tris^HCl, pH 8.0, 0.1% Tween 20 (TBS-T)
and 5% non-fat milk. Immunoblots were incubated overnight at 4‡C
with the various primary antibody solutions diluted in TBS-T with 5%
non-fat milk. Antisera dilutions and sources were as follows: FKBP12
(1:600 dilution, Santa Cruz); calcineurin AK (1:850 dilution, Trans-
duction Laboratories); IP3R type 3 (1:1000, Transduction Laborato-
ries) ; IP3R types 1 and 2, CT-1 and CT-2 (1:100) were raised against
the C-terminus of each subtype as described and characterised previ-
ously [17]; RyR types 1^3 (1:3000) raised against the region of low
homology situated between the predicted transmembrane domains 4
and 5 for RyR1 and RyR2 and against the D1 region of RyR3, as
characterised and described previously [23,29]. Nitrocellulose mem-
branes were washed three times in TBS-T for 30 min, incubated
with a 1:1000 dilution of horseradish peroxidase-linked anti-rabbit,
anti-mouse or anti-goat IgG (Dako) in TBS-T for 1 h. Blots were
washed as described above, then immunoreactive proteins were de-
tected with enhanced chemiluminescence (Amersham Pharmacia Bio-
tech) and quanti¢ed by densitometry (GeneGenius Gel Documenta-
tion and Analysis System/Syngene), with results obtained analysed as
absolute values (total integrated volume).
2.3. Treatment of crude microsomes and membranes with FK506
Crude microsomes and total membrane fractions were treated with
FK506 using a slight modi¢cation of the method described by Timer-
man et al. [7], to dissociate FKBP from terminal cisternae vesicles.
Membranes (3.5 mg protein/ml) and microsomes (3.5 mg protein/ml)
from the three tissue types were incubated in a ¢nal volume of 1 ml of
10 mM Tris-maleate pH 7.0, 0.1 mM NaCl, 0.3 M sucrose, 10 Wg/ml
aprotinin, leupeptin and pepstatin, containing 10 WM FK506 (diluted
in 0.1% methanol) at 22‡C or 37‡C, for 30 min. The samples were
then centrifuged at 100 000Ugmax for 30 min at 4‡C in a Beckman
Ultracentrifuge (Beckman Type 65 rotor) to yield a pellet and super-
natant (SN-1) fraction. This supernatant should contain the soluble
FKBP^FK506 complex. To ensure complete removal of FKBP12 the
pellet was washed by resuspension in 1 ml of the above bu¡er, rese-
dimented at 100 000Ugmax for 30 min at 4‡C (Sorval TY-65 rotor)
and the resulting pellet (P) and supernatant (SN-2) collected. This
pellet was washed super¢cially and resuspended in 1 ml of the above
bu¡er. All tissue preparations were also subjected to the above pro-
cedure with vehicle (0.1% methanol). Fractions were analysed by
SDS^PAGE and Western immunoblot analysis where equal volumes
of pellet (P) and supernatant (SN-1; SN-2) fractions were solubilised
in sample bu¡er before resolution on SDS^PAGE (FK506 was a
generous gift from Fujisawa GmbH, Munich, Germany).
2.4. Preparation of FKBP12^GST and GST fusion proteins
An FKBP12^GST fusion protein was prepared from a pGEX2TK
plasmid containing human FKBP12 cDNA, as described previously
[22]. In brief, 1 l XL-1 blue Escherichia coli transfected with this
FKBP12-pGEX2TK construct, or with pGEX2TK alone, was grown
at 37‡C in LB broth to an optical density at 600 nm of V0.5, then
was induced by addition of 1 mM isopropyl L-D-thiogalactoside, fol-
lowed by a further 2 h incubation at 25‡C. Bacteria were pelleted at
5000Ugmax for 10 min at 4‡C (5400 rpm, Sorval GS3 rotor), then
were resuspended in 25 ml of 0.1% Triton X-100, 100 Wg/ml lysozyme,
phosphate-bu¡ered saline (PBS). Suspensions were sonicated, centri-
fuged at 20 000Ugmax for 1 h at 4‡C (12 500 rpm, Sorval SS34 rotor),
and resultant supernatants were mixed with 1000 Wl (unpacked vol-
ume) of glutathione Sepharose 4B beads in PBS for 12^16 h at 4‡C.
Beads were pelleted at 200Ugmax for 2 min, were resuspended in 2 ml
of FKBP wash bu¡er (FKWB: 300 mM sucrose, 170 mM NaCl, 0.1%
CHAPS (3-((cholamidopropyl)dimethylammonio)-1-propane-sulfo-
nate), 2 mM dithiothreitol, 20 mM Tris^HCl pH 7.4 and protease
inhibitors) containing 0.05% sodium azide, then were stored for up
to 3 weeks at 4‡C.
2.5. FKBP12^GST a⁄nity precipitations
Proteins that interact with FKBP12 were isolated from solubilised
microsomal membranes by a modi¢cation of a previously described
procedure [30]. Protein (16 mg) from skeletal muscle, cardiac muscle
or brain crude microsomes was solubilised in 8 ml of 2% CHAPS,
500 mM NaCl, 2 mM dithiothreitol, 0.5 mM PMSF, 200 mM Tris^
HCl pH 7.4 for 1 h at 22‡C with shaking. Reactions were centrifuged
at 100 000Ugmax for 1 h (Beckman Type 42.1 rotor, 32 000 rpm, 4‡C),
then the solubilised material incubated with 40 Wg of FKBP12^GST
or GST protein, immobilised on agarose beads, overnight at 4‡C.
Beads were then pelleted, resuspended in 10 ml of FKWB, and divid-
ed into 10U1 ml aliquots. Complexes were incubated in the presence
of 10 WM FK506, or vehicle (0.1% methanol) for 2 h at 37‡C, then
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were washed six times with FKWB by repeated centrifugation and
resuspension of the beads (12 000 rpm for 10 s, Eppendorf microfuge).
Beads were ¢nally resuspended in 20 Wl of 1USDS^PAGE loading
bu¡er and were stored at 320‡C prior to resolution of 10 Wl of each
sample by SDS^PAGE.
3. Results
The distribution and relative levels of FKBP12, calcineurin
AK, RyR isoforms and IP3R isoforms were analysed in native
membranes and crude microsomes prepared from skeletal
muscle, heart and brain by Western immunoblot using pro-
tein- and isoform-speci¢c antisera. FKBP12 was expressed
ubiquitously in these tissues, co-migrating with pure recombi-
nant FKBP12 at 14 kDa (Fig. 1A). Densitometric analyses of
the combined immunoreactivity from total membrane and
cytosolic fractions revealed highest FKBP12 expression in
brain, which was approximately 3.0- and 2.5-fold higher
than that observed in skeletal and cardiac muscle, respectively
(Fig. 1A). FKBP12 was detected predominantly in skeletal
and cardiac muscle cytosol with minimal amounts evident in
total membrane fractions, in contrast, proportionally higher
levels of FKBP12 were observed in brain membranes (Fig.
1A). Approximately equal levels of FKBP12 were present in
skeletal muscle and brain microsomes, with much lower ex-
pression observed in cardiac microsomes (Fig. 1A). A higher
mobility FKBP12 immunoreactive band was detected in brain
microsomes and derived cytosolic fractions (Fig. 1A, lanes 4
and 7). This band, which was also apparent in cardiac micro-
somes when higher protein concentrations were analysed, has
been determined by other work using this antiserum (raised
against a C-terminal region of FKBP12, shared by FKBP12.6)
to be FKBP12.6 [10]. Calcineurin AK was detected in all tis-
sues (Fig. 1B), brain fractions had the richest expression levels
of this phosphatase, followed by skeletal muscle with lowest
expression observed in cardiac muscle preparations.
Studies examining the distribution of the di¡erent RyR and
IP3R isoforms among the rabbit tissues revealed the greatest
RyR1 levels in skeletal muscle membranes and microsomes,
with approximately 20-fold lower expression levels observed
in cardiac membranes and microsomes, and no expression
evident in brain (Fig. 1C). On the other hand, the greatest
Fig. 1. Representative immunoblots showing the relative expression
levels of (A) FKBP12, (B) calcineurin AK, (C) RyR isoforms and
(D) IP3R isoforms in various fractions prepared from skeletal
muscle, cardiac muscle and brain. A: Lane 1 contains pure human
recombinant FKBP12, lanes 2^7 contain fractions indicated, pre-
pared from skeletal muscle (lanes 2, 5), cardiac muscle (lanes 3, 6)
and brain (lanes 4, 7). B: Lanes 1^6 contain fractions indicated, de-
rived from skeletal muscle (lanes 1, 4) cardiac muscle (lanes 2, 5)
and brain (lanes 3, 6), respectively. C: (I) RyR1, (II) RyR2 and
(III) RyR3 immunoblots of skeletal muscle, cardiac muscle, brain
membranes (lanes 1^3) and derived microsomes (lanes 4^6), respec-
tively. For RyR3 bovine diaphragm was loaded (lane 7) as an inter-
nal control. D: (I) IP3R1, (II) IP3R2 and (III) IP3R3 immunoblots
of skeletal muscle, cardiac muscle, brain membranes (lanes 1^3) and
derived microsomes (lanes 4^6), respectively. Representative data
from three separate determinations are shown.
Fig. 2. Representative immunoblots showing the e¡ect of 10 WM
FK506 treatment (plus FK506) or vehicle alone (minus FK506) on
the distribution of (A) FKBP12 in skeletal muscle, cardiac muscle
and brain fractions and (B) calcineurin AK in brain fractions. Mi-
crosomes were treated with FK506 (10 WM) for 1 h at 22‡C or
37‡C as indicated, and derived ¢nal pellet (P) and initial (SN-1) and
¢nal supernatant (SN-2) analysed for FKBP12 or calcineurin immu-
noreactivity. A,B: Lane 1, original microsomes; lane 2, P plus
FK506; lane 3, P minus FK506; lane 4, SN-1 plus FK506; lane 5,
SN-1 minus FK506; lane 6, SN-2 plus FK506; lane 7, SN-2 minus
FK506 and lane 8, pure human recombinant FKBP12. Data shown
are representative of two identical experiments.
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expression of RyR2 was apparent in cardiac membranes and
microsomes, with substantial expression evident in brain (ap-
proximately 2.5-fold less) and no expression in skeletal muscle
(Fig. 1C). Finally, RyR3 levels were present at maximum
levels in brain microsomes with lower levels detected in car-
diac microsomes, and no expression in skeletal muscle (Fig.
1C). A higher RyR3 immunoreactive band was detected in
skeletal muscle membranes but not in derived microsomes.
All IP3R isoforms were expressed to relatively high levels in
brain microsomes and membrane fractions (Fig. 1D). IP3R2
was identi¢ed in cardiac fractions (Fig. 1D) and IP3R3 was
present in all tissues examined, with highest expression in
cardiac and brain membranes and microsomes, and minimal
expression observed in skeletal muscle microsomes (Fig. 1D).
It has been shown previously that high concentrations of
FK506 (10 WM) need to be incubated with solubilised terminal
cisternae prepared from skeletal muscle, to enable complete
removal of FKBP12 from this SR fraction [7]. The dissocia-
tion of FKBP12 from microsomes prepared from the three
tissue types was thus monitored, in the presence and absence
of this previously described FK506 treatment procedure.
Western blots with FKBP12 antisera revealed a di¡erent pro-
¢le of FKBP12 removal when comparing skeletal muscle mi-
crosomes with brain or cardiac microsomes. Results in Fig.
2A show that FK506 treatment was required to totally re-
move FKBP12 from skeletal muscle microsomes where signif-
icant di¡erences in FKBP12 removal from microsomes were
observed in the absence and presence of FK506. FKBP12
removal from skeletal muscle microsomes was temperature
dependent, with complete FKBP12 removal observed at
37‡C in the presence of FK506, and partial removal observed
at 22‡C (Fig. 2A). In striking contrast to the situation ob-
served in skeletal muscle, FKBP12 was removed completely
and equally e¡ectively, from both brain and cardiac micro-
somes, in the presence and absence of FK506. Similar results
were observed when incubations were performed at 22‡C, and
also with membrane fractions (results not shown). In fact
FKBP12 was found to dissociate from both brain and cardiac
microsomes and membranes during simple high-speed centri-
fugation (100 000Ugmax) alone. Higher levels of FKBP12.6
immunoreactivity were apparent in the supernatants derived
from FK506-treated brain and cardiac samples compared to
vehicle-treated preparations. Results in Fig. 2B demonstrate
that identical amounts of calcineurin AK remain in the brain
microsomal fractions and are removed from it in the presence
and absence of FK506. Similar results were observed for skel-
etal muscle microsomes (results not shown). The relationship
of calcineurin AK with cardiac microsomes was more di⁄cult
to monitor, owing to its lower levels of expression in this
tissue.
An FKBP12^GST fusion protein, immobilised on agarose
beads, was allowed to interact with protein solubilised from
brain, cardiac and skeletal muscle microsomes. Resulting
complexes were then probed with various antibodies in immu-
noblot assays (Fig. 3C^I) or stained with Coomassie R250
(Fig. 3A,B). Of all proteins tested, only a high apparent mo-
lecular weight protein (V500 kDa, Fig. 3A, lane 8) from
skeletal muscle bound to these beads. This protein was immu-
noreactive with the anti-type 1 RyR antibody (Fig. 3C) and
was speci¢cally associated with FKBP12, since it did not bind
to GST-only beads (Fig. 3A,C) and was displaced from the
FKBP12^GST fusion protein by treatment with 10 WM
FK506 (Fig. 3A,C). All other Ca2 release channels were
not detectable in FKBP12^GST a⁄nity precipitations from
tissues in which they are expressed (Fig. 3D^H). Similarly,
calcineurin AK was not detectable in such precipitates (Fig.
3I). A variety of conditions were used to determine whether
di¡ering bu¡er components (e.g. pH, NaCl, concentrations,
Ca2 and Mg2) could induce a high a⁄nity association of
the other Ca2 release channels or calcineurin with FKBP12.
However, no matter what conditions were employed only
skeletal muscle RyR1 was found to bind tightly with
FKBP12.
Fig. 3. CHAPS-solubilised membrane proteins from brain (lanes 2^
4), cardiac (lanes 5^7) or skeletal muscle (lanes 8^10) microsomes
were incubated with GST beads (lanes 4, 7, 10, 12) or with
FKBP12^GST beads (all other lanes). Reactions were subsequently
treated with 10 WM FK506 (lanes 3, 6, 9) or methanol vehicle (lanes
2, 5, 8). The resulting complexes were washed, resolved on 6%
(A, C^H) or 15% (B and I) SDS^PAGE gels, then stained with
Coomassie R250 (A and B), or blotted onto nitrocellulose for im-
munostaining with the following antibodies: C, anti-RyR1; D, anti-
RyR2; E, anti-RyR3; F, anti-IP3R1; G, anti-IP3R2; H, anti-
IP3R3; and I, anti-calcineurin AK. Lanes 11 and 12 are FKBP12^
GST (lane 11) and GST (lane 12) incubated in the absence of solu-
bilised microsomal proteins. Positive controls for immunoblots were
10 Wg of solubilised microsomal protein from skeletal muscle (A and
C) or brain (all other panels), loaded into lane 1 of these gels. Posi-
tions of molecular weight markers for SDS^PAGE are given on the
right hand side of A and B. Representative data of three separate
experiments are shown.
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4. Discussion
In initial experiments we measured the complement of RyR
isoforms, IP3R isoforms, FKBP12 and calcineurin in native
membranes and microsomes from brain, skeletal and cardiac
tissue, thus determining the range of endogenous Ca2 release
proteins that could potentially form a tight association with
FKBP12/12.6 in tissues which rely heavily on intracellular
Ca2 signalling. FKBP12 was detected predominantly in the
cytosol of all tissues, as previously described [3], with greatest
levels present in brain, in agreement with [3H]FK506 binding
studies of Steiner et al. [26]. High FKBP12 levels were also
evident in skeletal muscle and brain microsomes, with lower
expression apparent in cardiac microsomes. Much lower levels
of FKBP12.6 were detected compared to FKBP12, which was
identi¢ed predominantly in brain microsomes, with minimal
expression in cardiac microsomes. Interestingly, FKBP12.6
expression has not been described previously in brain. The
low levels of FKBP12.6 compared to FKBP12 in rabbit car-
diac microsomes were at ¢rst sight surprising, considering that
FKBP12.6 has been reported to be the major isoform in car-
diac microsomal membranes from canine heart [12,13]. How-
ever, recent studies have shown FKBP12.6 to be undetectable
in rabbit cardiomyocytes, with FKBP12 being the predomi-
nant isoform [31], and other work has shown that FKBP12
and FKBP12.6 are expressed in cardiac microsomes from di-
verse vertebrate species, the exception being canine micro-
somes, which only express FKBP12.6 [10].
The expression of Ca2 release channel isoforms in the
various tissue types agreed with the previous literature ¢nding
RyR1, RyR2 and RyR3 to be expressed predominantly in
skeletal muscle, heart and brain, respectively, with high levels
of RyR2 detected in brain [22,23,27], low levels of RyR1 and
RyR3 detected in heart [32,33], and RyR3 protein detected in
diaphragm [33]. Comparative levels of IP3R protein isoforms
have been analysed previously in rat tissue membranes, ex-
cluding skeletal muscle [25], but have for the most part been
analysed at an mRNA level [24,34,35]. It has been inferred
from mRNA estimations that IP3R2 is present at high levels
in skeletal muscle. However, this isoform was not detected in
rabbit skeletal microsomes, which only expressed minimal lev-
els of the IP3R3 isoform. Brain and cardiac microsomes and
membranes expressed all three IP3R isoforms to di¡ering de-
grees [25] with IP3R1 expression found to very minimal levels
in cardiac tissue. The calcineurin AK expression pro¢le agrees
with previous studies, with lowest expression evident in car-
diac tissue which predominantly expresses the calcineurin AL
isoform [36].
Although FKBP12 is predominantly cytosolic, it has been
found to be very tightly associated with solubilised skeletal
muscle terminal cisternae, but not heart SR [7,13]. This
FKBP12 terminal cisternae association requires high concen-
trations of FK506 for disruption, and is assumed to occur
through the well described integral association of RyR1
with FKBP12 [7^9]. Our results showed that this tight
FKBP12^membrane association was also evident in unsolubi-
lised native microsomes, where identical temperature depen-
dent FK506 treatments as those described by Timerman et al.
[7,13] were essential to enable total dissociation of FKBP12
from skeletal muscle but not cardiac microsomes. The nature
of the association between FKBP12 and brain microsomes
has been assumed to be similar to that displayed between
FKBP12 and skeletal muscle, owing to studies showing that
FKBP12 associates tightly with the cerebellar IP3R1 complex,
requiring FK506 for removal [19,20]. However, our work
found that FKBP12 was very readily displaced from brain
microsomes in an FK506 independent manner, suggesting
that FKBP12 was not an integral subcomponent of the array
of Ca2 release channels expressed in brain. Much lower
FKBP12.6 levels were detected in cardiac and brain frac-
tions, and it appeared that FK506 was more e¡ective in re-
moving FKBP12.6 from both these fractions, however this
was di⁄cult to quantify as FKBP12.6 expression was ex-
tremely low compared to FKBP12. It has been suggested
that association of FKBPs with intracellular Ca2 release
channels may favour the more abundant FKBP isoform
present in the cytosol [37]. More work needs to be performed
to investigate the relevance of the modulation of Ca2 release
channels in brain by endogenous FKBP12.6 in the presence of
vastly higher levels of endogenous FKBP12, as observed in
this study.
Yeast two-hybrid studies have found that FKBP12 binds to
IP3R1 at a leucyl-prolyl dipeptide motif, which anchors calci-
neurin to this hydrophobic IP3R^FKBP12 complex [38].
Analogous FKBP12/12.6 dipeptide binding domains are con-
served through all types of IP3R and RyR isoforms. Quanti-
¢cation of the a⁄nity of interaction between FKBP12 and all
endogenously expressed RyR isoforms, IP3R isoforms and
calcineurin among excitable tissue types has not been ana-
lysed. This is important in order to understand the dynamics
of FKBP12 control of intracellular Ca2 signalling, and the
constitutive subunit composition of RyR and IP3R isoforms
in these di¡erent tissue types. Results of the present study
showed that skeletal muscle RyR1 bound tightly to FKBP12
a⁄nity beads in an FK506 displaceable manner but that in
sharp contrast, none of the other Ca2 release channels or
calcineurin AK expressed in brain, heart or skeletal muscle
bound speci¢cally to FKBP12^GST under a variety of con-
ditions. These data agree with our ¢ndings on the association
of FKBP12 with the diverse native tissue types, and the many
studies describing high a⁄nity RyR1^FKBP12 association.
However, once again they are in contrast to studies describing
tight FKBP12 association with the IP3R^calcineurin complex
in brain. It is possible that these discrepancies result from
species di¡erences, di¡erent preparations or methodologies
used. Although the tight binding of calcineurin and
FKBP12 has not been broadly explored, some controversy
does however exist with respect to the described integral asso-
ciation of FKBP12 with IP3Rs. In this respect a very recent
study detected no direct interaction between cerebellar IP3R1
and FKBP12, and showed that the proteolytic fragment of
IP3R1 containing the proposed FKBP12 binding site is not
retained by GST^FKBP12, in contrast to the situation with
RyR1 [18]. The work described in the present study further
extends this strongly suggesting that none of the endogenous
IP3R isoforms expressed in brain, heart, or skeletal muscle is
tightly associated with FKBP12. This also agrees with studies
that have been unable to demonstrate a functional e¡ect of
FK506 and FKBP12 on IP3-induced Ca2 release in di¡erent
cell types [21]. We proposes that a constitutive tight binding
association between IP3R isoforms and FKBP12 may be ten-
uous at best. We furthermore suggest a lack of integral asso-
ciation between FKBP12 and RyR3 in brain and heart, which
agrees with recent work hypothesising that comparative di¡er-
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ences in RyR1 and RyR3 gating behaviour may be due to the
lower a⁄nity of RyR3 for FKBP12 [39].
The results of this study do not imply that FKBP12 does
not functionally associate or modulate intracellular Ca2 re-
lease channels besides RyR1. Di¡erential structural con-
straints of these receptors compared to RyR1 may impede
constitutive high a⁄nity FKBP12 association with these
Ca2 release channels. Modulation of receptor conformation
induced by cellular events such as protein folding, phosphor-
ylation, or the association of other accessory proteins may
induce both low and high a⁄nity FKBP12 receptor associa-
tion causing altered channel function. In this respect it is
interesting to note that FKBP12.6 has been found to disso-
ciate from cardiac RyR2 in response to RyR2 phosphoryla-
tion [15]. In conclusion, the results of the present study sug-
gest that the properties of skeletal muscle RyR1 are unique
among intracellular Ca2 release channel isoforms with re-
spect to their tight constitutive association with FKBP12.
This integral association may underlie exclusive features of
RyR1-induced skeletal muscle excitation^contraction cou-
pling. The ¢ndings of this work are important in gaining an
understanding of the di¡erential mechanisms by which the
FKBP12 family interacts with and regulates endogenous in-
tracellular Ca2 channels in di¡erent tissue types.
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